Sanofi Chief Executive Paul Hudson said on Monday that the company has not made a final decision yet on how it plans to split ...

The Waltham, Massachusetts-based company, which was incorporated in 2019, plans to use the IPO proceeds to advance the ...

Multiple sclerosis (MS) affects the brain and spinal cord limiting movement, vision, and others. Known as an autoimmune disorder, this chronic disease of the central nervous system slows or blocks ...

Phase IV studies demonstrate the consistent safety and high efficacy of MAVENCLAD on NEDA-3, MRI and cognition outcomes over four yearsNew data on ...

[10] Conti P, Kempuraj D. Important role of mast cells in multiple sclerosis. Mult Scler Relat Disord. 2016;5:77-80. [11] Skaper SD, Facci L, Giusti P. Mast cells, glia and neuroinflammation: partners ...

B.Riley Financial analyst William Wood has reiterated their bullish stance on IMUX stock, giving a Buy rating on September 16. William Wood ...

The company, backed by drugmaker Bristol-Myers Squibb, is looking to raise as much as $211.7 million by offering 11.76 million shares priced between $16 and $18 each. The proposed offering comes ...

As usual, a second trial will be needed before UCB and Biogen can file dapirolizumab pegol with regulators. It will be called ...

Today is an important day for Cardarelli as it inaugurates a department dedicated to patients with multiple sclerosis. We ...

Sanofi to receive an exclusive right of first negotiation for Ventyx’s CNS-penetrant NLRP3 inhibitor VTX3232SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: VTYX) (“Ventyx”), a clinical-stage ...

Biogen markets several multiple sclerosis drugs including Plegridy ... Biogen has several drug candidates in phase 3 trials ...